Skip to main content

Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: do not confound access route and specific drug complications!

To the Editor:

Owen et al. [1] recently reported in the Journal a low incidence of adverse events associated with peripheral intravenous vasopressor administration in a systematic review and meta-analysis.

While the authors must be congratulated for their interesting review on this relevant question, we think that their findings require some caution. First, none of the studies from the Owen et al. [1] report indicates the vasopressor concentration used, while it has been reported that peripheral intravenous vasopressor toxicity relies on vasopressor concentration, and that using lowered solutions of a lower concentration helps to improve tolerance [2], which noticeably increases the safety of peripheral intravenous vasopressor administration. Second, time to exposure directly affects incidence of complications: as stated by Owen et al. [1], among adult studies, the average duration of peripheral intravenous vasopressor administration is 12–24 h, which limits the risk. Third, the intrinsic peripheral venous toxicity is different among vasopressors, related to their respective potency [3]. Fourth, the authors only considered local anatomic events, but excluded potential systemic effects, such as tachyarrhythmia and hypotension. Nonetheless, these life-threatening complications may be due to incidents specifically related to the peripheral intravenous access, like for example, during arm compression for nursing. On the other hand, central venous access per se fully prevents occurrence of such mechanical events. Finally, it should be kept in mind that some complications are inherent to the access route itself: e.g., extravasation after peripheral intravenous catheter versus pneumothorax after sub-clavicular puncture. Conversely, local ischemia, necrosis, and tachyarrhythmia must be considered as complications specifically related to the vasopressor drug by itself, e.g., due to its intrinsic properties.

Beyond these limitations, we fully agree with Owen et al. [1] that the adverse events’ incidence and severity after peripheral vasopressors administration are low. Because the rate of adverse events resulting from peripheral vasopressor administration is not different from those from central lines [4], there is no reason to delay their use, especially for the sicker patients cared for in the prehospital and/or in-hospital setting [5].

Availability of supporting data

Not applicable.

References

  1. 1.

    Owen VS, Rosgen BK, Cherak SJ, Ferland A, Stelfox HT, Fiest KM, et al. Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: a systematic review and meta-analysis. Crit Care. 2021;25:146.

    Article  Google Scholar 

  2. 2.

    Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Peripheral administration of VM. J Hosp Med. 2015;10(9):581–5.

    Article  Google Scholar 

  3. 3.

    Tian DH, Smyth C, Keijzers G, Macdonald SP, Peake S, Udy A, Delaney A, et al. Safety of peripheral administration of vasopressor medications: a systematic review. Emerg Med Australas. 2020;32(2):220–7.

    Article  Google Scholar 

  4. 4.

    Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early use of norepinephrine in septic shock resuscitation (CENSER): a randomized trial. Am J Respir Crit Care Med. 2019;199(9):1097–105.

    CAS  Article  Google Scholar 

  5. 5.

    Li Y, Li H, Zhang D. Timing of norepinephrine initiation in patients with septic shock: a systematic review and meta-analysis. Crit Care. 2020;24(1):488.

    Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Affiliations

Authors

Contributions

RJ and BV wrote and revised the manuscript. Both authors read and approved the final manuscript.

Corresponding author

Correspondence to Romain Jouffroy.

Ethics declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

RJ and BV consent for publication.

Competing interests

RJ and BV have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jouffroy, R., Vivien, B. Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: do not confound access route and specific drug complications!. Crit Care 25, 183 (2021). https://doi.org/10.1186/s13054-021-03605-6

Download citation